← All indications
Bronchiolitis
Inflammation of the BRONCHIOLES.
Subtype terms (2)
More specific conditions that are subtypes of Bronchiolitis in the MeSH hierarchy.
- Bronchiolitis Obliterans
21 drugs (19 approved, 2 experimental)
- Bronchiolitis, Viral
6 drugs (5 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (12)
Phase 3 trials (11)
Phase 2 trials (13)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (49)
- Gilead Sciences
- Hamad Medical Corporation
- University of Pennsylvania
- University of Pittsburgh
- Baqiyatallah Medical Sciences University
- Cornell University
- Harvard University
- Duke University
- Katholieke Universiteit Leuven
- Johns Hopkins University
- Michigan State University
- New York University
- Osaka University
- Seoul National University
- Sykehuset i Vestfold HF
- Sykehuset Innlandet HF
- Sorlandet Hospital HF
- University of Limpopo
- University of Maryland
- University of Michigan
- University of Oslo
- University of Rochester
- University of Tennessee
- University of Bergen
- Assiut University
- Columbia University
- Kecioren Education and Training Hospital
- University of California, Davis
- University of Cincinnati
- University of Utah
- +19 more
Organization Involved with Phase 3 Indications (41)
- Advanced Inhalation Therapies Ltd
- Merck
- APT Pharmaceuticals, Inc.
- Novartis
- GlaxoSmithKline
- Inmunotek S.L.
- Pari Pharma GmbH
- Hôpital de L'Enfance
- Hospital Universitario Fundación Alcorcón
- Institut National de la Santé Et de la Recherche Médicale, France
- Mansoura University
- McGill University
- Sheikh Khalifa Medical City
- Unidad de Investigacion Medica en Epidemiologia Clinica
- University of Hamburg
- University of Louisville
- University of Ottawa
- University of Southern California
- University of Toronto
- University of Alberta
- University of California, San Francisco
- University of Copenhagen
- International Center for Diarrheal Disease Research
- Universidad Autonoma de Barcelona
- University of Verona
- University of Paris
- University of New South Wales
- University of Western Ontario
- Canadian Institutes of Health Research (CIHR)
- United States Agency for International Development
- +11 more
Organization Involved with Phase 2 Indications (29)
- Incyte
- AstraZeneca
- Reata Pharmaceuticals, Inc.
- Telethon Kids Institute
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Washington
- Northwell Health
- Northwestern University
- Queen's University, Belfast
- The Canadian Blood and Marrow Transplant Group
- University Diego Portales
- University of Melbourne
- University of Regensburg
- Tel Aviv University
- University of Basel
- Food and Drug Administration
- Southern Medical University
- Sun Yat-Sen University
- University of Montreal
- University of Texas at Houston
- Paris Diderot University
- Clinica Vespucio, Santiago, Chile
- Ben Gurion University
- Technical University of Dresden
- ClinAssess GmbH
- Northeast Ohio Medical University
- Beyond Air Ltd
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (24)
- Pfizer
- Mallinckrodt
- Azad University
- Case Western Reserve University
- Hormozgan University of Medical Sciences
- Hospital General de Niños Pedro de Elizalde
- Indiana University
- Makassed General Hospital
- Medical College of Wisconsin
- University of Oulu
- Chongqing Medical University
- Laval University
- University of California, Los Angeles
- University of Colorado, Denver
- University of Ulsan
- Bar Ilan University
- The University of Hong Kong
- University of Sao Paulo
- KhonKaen University
- Centers for Medicare and Medicaid Services
- National Research Council of Thailand
- Government of Hong Kong
- University Clermont Auvergne
- The University of Texas, Dallas